Liraglutide or Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Non-Insulin-Dependent
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
Trial Timeline
Oct 1, 2014 → Dec 1, 2016
NCT ID
NCT02299388About Liraglutide or Placebo
Liraglutide or Placebo is a approved stage product being developed by Novo Nordisk for Diabetes Mellitus, Non-Insulin-Dependent. The current trial status is completed. This product is registered under clinical trial identifier NCT02299388. Target conditions include Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Non-Insulin-Dependent were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02299388 | Approved | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Non-Insulin-Dependent